Losartan has been shown to reduce IP in TNBS-induced colitis mice, enhance OCLN and ZO-1 gene expression lowering circulating LPS in SHR, and decrease colonic permeability in LPS-treated Sprague-Dawley rats [90,91,92]. This evidence concerns the gene TJP1 and colitis.